BioSig Invited to Attend and Sponsor Venice Arrhythmias 2022
October 12 2022 - 10:00AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”) an advanced digital signal processing technology company
delivering unprecedented accuracy and precision to intracardiac
signal visualization with its proprietary PURE EP™ System, today
announced that it has been invited to attend the 17th Edition
Venice Arrhythmias 2022 Congress—a Heart Rhythm Society sponsored
program taking place from October 13-15, 2022 in Venice, Italy.
During the event, BioSig’s leadership and commerical teams will
introduce the PURE EP™ System to the European EP
(electrophysiology) market for the first time. Following the recent
launch of PURE EP™ Software Version 6 with ACCUVIZ™ Module, the
Company will be showcasing the highly differentiated features of
its digital signal processing technology, which includes advanced
signal processing automation, elevated visualization of clear
cardiac signal information, and TRUSOURCE™, a comprehensive
procedural analysis and report.
“It is an honor to be interacting with many talented physicians
who are breaking new ground in electrophysiology science. Their
research is impacting technological advancement in the industry,”
commented Kenneth L. Londoner, Chairman, and CEO of BioSig
Technologies, Inc. “I could not be more excited to
demonstrate how the PURE EP™ System can provide deeper clinical
insights and simplify procedural workflows to this science-based
community. As a company, we celebrate their clinical legacy
and embody their investment in this critical field of
healthcare.”
About Venice Arrhythmias 2022
Venice Arrhythmias 2022 is a world-renown congress that convenes
global experts and innovators in the field of heart rhythm
disorders to discuss the latest scientific advances and
cutting-edge technologies in cardiac electrophysiology, pacing, and
clinical arrhythmology. This year’s—17th edition— program will be
led by course directors and presidents of the Venice Arrhythmias
Congress: Andrea Natale, MD, FHRS, Executive Medical Director,
Texas Cardiac Arrhythmia Institute at St. David's Medical Center in
Austin, Texas; Sakis Themistoclakis, MD, PhD, Director of
Cardiology of Dell'Angelo Hospital in Venice-Mestre, Italy; and
Antonio Raviele, MD, FHRS, President of the Alliance to Fight
Atrial Fibrillation (ALFA).
About BioSig Technologies
BioSig Technologies is an advanced digital signal processing
technology company bringing never-before-seen insights to the
treatment of cardiovascular arrhythmias. Through collaboration with
physicians, experts, and healthcare leaders across the field of
electrophysiology (EP), BioSig is committed to addressing
healthcare’s biggest priorities — saving time, saving costs, and
saving lives.
The Company’s first product, the PURE EP™ System, an FDA 510(k)
cleared non-invasive class II device, provides superior, real-time
signal visualization allowing physicians to perform insight-based,
highly targeted cardiac ablation procedures with increased
procedural efficiency and efficacy.
The PURE EP™ System is currently in a national commercial launch
and an integral part of well-respected healthcare systems, such as
Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic,
and Kansas City Heart Rhythm Institute. In a blinded clinical
study recently published in the Journal of Cardiovascular
Electrophysiology, electrophysiologists rated PURE EP™ as
equivalent or superior to conventional systems for 93.6% of signal
samples, with 75.2% earning a superior rating.
The global EP market is projected to reach $16B in 2028 with a
11.2% growth rate.1
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market conditions and the
Company’s intended use of proceeds, (ii) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (iii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iv)
difficulties in obtaining financing on commercially reasonable
terms; (v) changes in the size and nature of our competition; (vi)
loss of one or more key executives or scientists; and (vii)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
1 Global Market Insights Inc. March 08, 2022.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road, 1st Floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024